89 related articles for article (PubMed ID: 25547405)
41. R-253 disrupts microtubule networks in multiple tumor cell lines.
Gururaja TL; Goff D; Kinoshita T; Goldstein E; Yung S; McLaughlin J; Pali E; Huang J; Singh R; Daniel-Issakani S; Hitoshi Y; Cooper RD; Payan DG
Clin Cancer Res; 2006 Jun; 12(12):3831-42. PubMed ID: 16778111
[TBL] [Abstract][Full Text] [Related]
42. Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers.
Hamel E; Lin CM; Flynn E; D'Amato RJ
Biochemistry; 1996 Jan; 35(4):1304-10. PubMed ID: 8573587
[TBL] [Abstract][Full Text] [Related]
43. Sulphamoylated Estradiol Analogue Induces Reactive Oxygen Species Generation to Exert Its Antiproliferative Activity in Breast Cancer Cell Lines.
Lebelo MT; Joubert AM; Visagie MH
Molecules; 2020 Sep; 25(18):. PubMed ID: 32971805
[TBL] [Abstract][Full Text] [Related]
44. Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance.
Fryknäs M; Gullbo J; Wang X; Rickardson L; Jarvius M; Wickström M; Hassan S; Andersson C; Gustafsson M; Westman G; Nygren P; Linder S; Larsson R
BMC Cancer; 2013 Aug; 13():374. PubMed ID: 23919498
[TBL] [Abstract][Full Text] [Related]
45. Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization.
van Vuuren RJ; Botes M; Jurgens T; Joubert AM; van den Bout I
Cancer Cell Int; 2019; 19():1. PubMed ID: 30622437
[TBL] [Abstract][Full Text] [Related]
46. 2-methoxyestradiol as a potential cytostatic drug in gliomas?
Kirches E; Warich-Kirches M
Anticancer Agents Med Chem; 2009 Jan; 9(1):55-65. PubMed ID: 19149482
[TBL] [Abstract][Full Text] [Related]
47. [Biosynthesis and microbial transformation of griseofulvin and carcinogenesis and prevention of cancer by estrogens].
Sato Y
Yakugaku Zasshi; 1995 Nov; 115(11):892-908. PubMed ID: 8568634
[TBL] [Abstract][Full Text] [Related]
48. Correction to: Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization.
van Vuuren RJ; Botes M; Jurgens T; Joubert AM; van den Bout I
Cancer Cell Int; 2020; 20():308. PubMed ID: 32684845
[TBL] [Abstract][Full Text] [Related]
49. An Investigation to Study the Role of Novel Rhenium Compounds on Endometrial Uterine Cancer Cell Lines.
Krauss C; Aurelius C; Johnston K; Bartlette V; Gavin S; Cuffee J; Banerjee S; Wiseniewsky S; Mandal S; Banerjee HN
J Can Res Updates; 2020; 9():102-106. PubMed ID: 34354788
[TBL] [Abstract][Full Text] [Related]
50. Structure-activity relationship and properties optimization of a series of quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway.
Nencini A; Pratelli C; Quinn JM; Salerno M; Tunici P; De Robertis A; Valensin S; Mennillo F; Rossi M; Bakker A; Benicchi T; Cappelli F; Turlizzi E; Nibbio M; Caradonna NP; Zanelli U; Andreini M; Magnani M; Varrone M
Eur J Med Chem; 2015 May; 95():526-45. PubMed ID: 25847770
[TBL] [Abstract][Full Text] [Related]
51. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
[TBL] [Abstract][Full Text] [Related]
52. Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.
Beaulieu PL; Bolger G; Deon D; Duplessis M; Fazal G; Gagnon A; Garneau M; LaPlante S; Stammers T; Kukolj G; Duan J
Bioorg Med Chem Lett; 2015 Mar; 25(5):1140-5. PubMed ID: 25599836
[TBL] [Abstract][Full Text] [Related]
53. Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.
Nguyen ST; Kwasny SM; Ding X; Cardinale SC; McCarthy CT; Kim HS; Nikaido H; Peet NP; Williams JD; Bowlin TL; Opperman TJ
Bioorg Med Chem; 2015 May; 23(9):2024-34. PubMed ID: 25818767
[TBL] [Abstract][Full Text] [Related]
54. Discovery of a potent, orally available dual CysLT₁ and CysLT₂ antagonist with dicarboxylic acid.
Itadani S; Takahashi S; Ima M; Sekiguchi T; Aratani Y; Egashira H; Matsumura N; Inoue A; Yonetomi Y; Fujita M; Nakayama Y; Takeuchi J
Bioorg Med Chem; 2015 May; 23(9):2079-97. PubMed ID: 25800431
[TBL] [Abstract][Full Text] [Related]
55. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
[TBL] [Abstract][Full Text] [Related]
56. Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.
Espinosa DA; Gutierrez GM; Rojas-López M; Noe AR; Shi L; Tse SW; Sinnis P; Zavala F
J Infect Dis; 2015 Oct; 212(7):1111-9. PubMed ID: 25762791
[TBL] [Abstract][Full Text] [Related]
57. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model.
Nambiar J; Clarke AW; Shim D; Mabon D; Tian C; Windloch K; Buhmann C; Corazon B; Lindgren M; Pollard M; Domagala T; Poulton L; Doyle AG
MAbs; 2015; 7(3):638-50. PubMed ID: 25751125
[TBL] [Abstract][Full Text] [Related]
58. SAH derived potent and selective EZH2 inhibitors.
Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
[TBL] [Abstract][Full Text] [Related]
59. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.
Ogata K; Shimizu T; Masumoto H; Oguma T; Sugiyama N; Kunitada S
Thromb Res; 2015 Apr; 135(4):594-601. PubMed ID: 25700621
[TBL] [Abstract][Full Text] [Related]
60. A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability.
Payne CE; Brown AR; Theile JW; Loucif AJ; Alexandrou AJ; Fuller MD; Mahoney JH; Antonio BM; Gerlach AC; Printzenhoff DM; Prime RL; Stockbridge G; Kirkup AJ; Bannon AW; England S; Chapman ML; Bagal S; Roeloffs R; Anand U; Anand P; Bungay PJ; Kemp M; Butt RP; Stevens EB
Br J Pharmacol; 2015 May; 172(10):2654-70. PubMed ID: 25625641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
